This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Mark Your Calendar for Next Year's Event!
May 9-12, 2022Hynes Convention Center, Boston

Kallanthottathil G. Rajeev, PhD
Vice Presideent, CMC at Verve Therapeutics


Kallanthottathil G. Rajeev serves as Vice President, Chemistry at Verve Therapeutics, Cambridge, Massachusetts, USA, where he joined as the second full-time employee. Dr. Rajeev has over 20 years of experience in developing nucleic acid therapeutics. Prior to joining Verve, Rajeev served as senior fellow of intellectual property and as a senior director of drug discovery at Alnylam Pharmaceuticals. In his 14 years with the drug discovery team at Alnylam, Rajeev played a key leadership role in the development of siRNA GalNAc conjugate and LNP delivery platforms, and in the design and evaluation of siRNAs for clinical development. Prior to Alnylam, Rajeev worked for Ionis Pharmaceuticals on high-affinity antisense oligonucleotides (ASO) and ASO-small molecule conjugates. He has co-authored more than 60 peer-reviewed manuscripts and is a co-inventor of more than 100 issued U.S. patents. Rajeev earned his Ph.D. in chemistry in the lab of Professor K. N. Ganesh at the National Chemical Laboratory, Pune, India, and was a postdoctoral researcher at the University of Utah, Salt Lake City, where he worked with Professor Arthur D. Broom.

Agenda Sessions

  • ROOM 204AB: Targeted Delivery of Base Editors to Hepatocytes in vivo